<DOC>
	<DOC>NCT02404389</DOC>
	<brief_summary>This is a randomized, vehicle controlled, active comparator, parallel group, study with a total duration of 24 weeks including screening and follow-up. Study drug is applied topically for 2 cycles of 4 week treatment, separated by 4 weeks off-treatment. Assessors of study endpoints are blinded to treatment allocation.</brief_summary>
	<brief_title>Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis, Actinic</mesh_term>
	<criteria>At least five (5) AK lesions within an area of 25 cm2, on the face (at least 2 cm from the periocular areas, lips, nares and ears) and/or balding scalp Presence of at least one additional visible or palpable non hyperkeratotic AK lesion outside of the selected area atopic dermatitis, eczema, psoriasis, rosacea or other possible confounding skin conditions on face or balding scalp Invasive tumors within the treatment area Women of childbearing potential Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Actinic keratosis, patients, topical, lesion count, clearance rate</keyword>
</DOC>